Furthermore, a study done on breast cancer patients identified that tumors expressing high levels of both iNOS and COX-2 had dismal survival outcomes compared with over 95% survival in patients with low expression of both enzymes [45]. This evidence concerns the gene PTGS2 and breast cancer.